296 related articles for article (PubMed ID: 34225789)
21. Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial.
Boyapati A; Wipperman MF; Ehmann PJ; Hamon S; Lederer DJ; Waldron A; Flanagan JJ; Karayusuf E; Bhore R; Nivens MC; Hamilton JD; Sumner G; Sivapalasingam S
J Infect Dis; 2021 Dec; 224(11):1830-1838. PubMed ID: 34496013
[TBL] [Abstract][Full Text] [Related]
22. Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION.
Kloka J; Friedrichson B; Dauth S; Foldenauer AC; Bulczak-Schadendorf A; Vehreschild MJGT; Matos FM; Riera-Mestre A; van Asselt ADI; De Robertis E; Juskeviciene VT; Meybohm P; Tomescu D; Lacombe K; Stehouwer CDA; Zacharowski K;
Trials; 2022 Aug; 23(1):688. PubMed ID: 35986390
[TBL] [Abstract][Full Text] [Related]
23. Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Huang DQ; Ajmera V; Tomaszewski C; LaFree A; Bettencourt R; Thompson WK; Smith DM; Malhotra A; Mehta RL; Tolia V; Yin J; Insel PA; Leachman S; Jung J; Collier S; Richards L; Woods K; Amangurbanova M; Bhatt A; Zhang X; Penciu OM; Zarich S; Retta T; Harkins MS; Teixeira JP; Chinnock B; Utay NS; Lake JE; Loomba R
Adv Ther; 2023 Nov; 40(11):4805-4816. PubMed ID: 37615850
[TBL] [Abstract][Full Text] [Related]
24. High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study-VitCov Trial.
Jaun F; Boesing M; Lüthi-Corridori G; Abig K; Makhdoomi A; Bloch N; Lins C; Raess A; Grillmayr V; Haas P; Schuetz P; Gabutti L; Muser J; Leuppi-Taegtmeyer AB; Giezendanner S; Brändle M; Leuppi JD
Trials; 2022 Feb; 23(1):114. PubMed ID: 35120577
[TBL] [Abstract][Full Text] [Related]
25. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial.
Jeronimo CMP; Farias MEL; Val FFA; Sampaio VS; Alexandre MAA; Melo GC; Safe IP; Borba MGS; Netto RLA; Maciel ABS; Neto JRS; Oliveira LB; Figueiredo EFG; Oliveira Dinelly KM; de Almeida Rodrigues MG; Brito M; Mourão MPG; Pivoto João GA; Hajjar LA; Bassat Q; Romero GAS; Naveca FG; Vasconcelos HL; de Araújo Tavares M; Brito-Sousa JD; Costa FTM; Nogueira ML; Baía-da-Silva DC; Xavier MS; Monteiro WM; Lacerda MVG;
Clin Infect Dis; 2021 May; 72(9):e373-e381. PubMed ID: 32785710
[TBL] [Abstract][Full Text] [Related]
26. Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.
Lasky JA; Fuloria J; Morrison ME; Lanier R; Naderer O; Brundage T; Melemed A
Adv Ther; 2021 Jan; 38(1):782-791. PubMed ID: 33108622
[TBL] [Abstract][Full Text] [Related]
27. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019.
Dandachi D; Geiger G; Montgomery MW; Karmen-Tuohy S; Golzy M; Antar AAR; Llibre JM; Camazine M; Díaz-De Santiago A; Carlucci PM; Zacharioudakis IM; Rahimian J; Wanjalla CN; Slim J; Arinze F; Kratz AMP; Jones JL; Patel SM; Kitchell E; Francis A; Ray M; Koren DE; Baddley JW; Hill B; Sax PE; Chow J
Clin Infect Dis; 2021 Oct; 73(7):e1964-e1972. PubMed ID: 32905581
[TBL] [Abstract][Full Text] [Related]
28. A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste.
Chupp G; Spichler-Moffarah A; Søgaard OS; Esserman D; Dziura J; Danzig L; Chaurasia R; Patra KP; Salovey A; Nunez A; May J; Astorino L; Patel A; Halene S; Wang J; Hui P; Patel P; Lu J; Li F; Gan G; Parziale S; Katsovich L; Desir GV; Vinetz JM
medRxiv; 2022 Jan; ():. PubMed ID: 35132421
[TBL] [Abstract][Full Text] [Related]
29. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19.
Nicastri E; Marinangeli F; Pivetta E; Torri E; Reggiani F; Fiorentino G; Scorzolini L; Vettori S; Marsiglia C; Gavioli EM; Beccari AR; Terpolilli G; De Pizzol M; Goisis G; Mantelli F; Vaia F; Allegretti M;
EClinicalMedicine; 2022 Jun; 48():101450. PubMed ID: 35582123
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Gunst JD; Staerke NB; Pahus MH; Kristensen LH; Bodilsen J; Lohse N; Dalgaard LS; Brønnum D; Fröbert O; Hønge B; Johansen IS; Monrad I; Erikstrup C; Rosendal R; Vilstrup E; Mariager T; Bove DG; Offersen R; Shakar S; Cajander S; Jørgensen NP; Sritharan SS; Breining P; Jespersen S; Mortensen KL; Jensen ML; Kolte L; Frattari GS; Larsen CS; Storgaard M; Nielsen LP; Tolstrup M; Sædder EA; Østergaard LJ; Ngo HTT; Jensen MH; Højen JF; Kjolby M; Søgaard OS
EClinicalMedicine; 2021 May; 35():100849. PubMed ID: 33903855
[TBL] [Abstract][Full Text] [Related]
31. Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial.
Legacy M; Seely D; Conte E; Psihogios A; Ramsay T; Fergusson DA; Kanji S; Simmons JG; Wilson K
BMJ Open; 2022 Mar; 12(3):e057024. PubMed ID: 35241474
[TBL] [Abstract][Full Text] [Related]
32. Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial.
Ben Abdallah S; Mhalla Y; Trabelsi I; Sekma A; Youssef R; Bel Haj Ali K; Ben Soltane H; Yacoubi H; Msolli MA; Stambouli N; Beltaief K; Grissa MH; Khrouf M; Mezgar Z; Loussaief C; Bouida W; Razgallah R; Hezbri K; Belguith A; Belkacem N; Dridi Z; Boubaker H; Boukef R; Nouira S
Clin Infect Dis; 2023 Jan; 76(2):185-191. PubMed ID: 36367144
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.
Bauer RN; Teterina A; Shivram H; McBride J; Rosenberger CM; Cai F; Bao M; Tsai L; Gordon O; Lee IT; Wallin JJ; Porter D; Juneja K; Camus G; Rosas IO; Wildum S
Clin Transl Sci; 2023 Jun; 16(6):1049-1062. PubMed ID: 36929625
[TBL] [Abstract][Full Text] [Related]
34. Early identification and severity prediction of acute respiratory infection (ESAR): a study protocol for a randomized controlled trial.
Yuan G; Wang H; Zhao Y; Mao E; Li M; Wang R; Zhou F; Jin S; Zhang Z; Xu K; Xu J; Liang S; Li X; Jiang L; Zhang L; Song J; Yang T; Guo J; Zhang H; Zhou Y; Wang S; Qiu C; Jiang N; Ai J; Wu J; Zhang W
BMC Infect Dis; 2022 Jul; 22(1):632. PubMed ID: 35858876
[TBL] [Abstract][Full Text] [Related]
35. Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial.
Eltahan NH; Elsawy NH; Abdelaaty KM; Elhamaky AS; Hassan AH; Emara MM
Respir Res; 2024 Feb; 25(1):97. PubMed ID: 38389078
[TBL] [Abstract][Full Text] [Related]
36. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
Somersan-Karakaya S; Mylonakis E; Menon VP; Wells JC; Ali S; Sivapalasingam S; Sun Y; Bhore R; Mei J; Miller J; Cupelli L; Forleo-Neto E; Hooper AT; Hamilton JD; Pan C; Pham V; Zhao Y; Hosain R; Mahmood A; Davis JD; Turner KC; Kim Y; Cook A; Kowal B; Soo Y; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
J Infect Dis; 2022 Dec; 227(1):23-34. PubMed ID: 35895508
[TBL] [Abstract][Full Text] [Related]
37. Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP) protocol and statistical analysis plan: a prospective, multicentre, double-blind, randomized, placebo controlled clinical trial.
Vine J; Berlin N; Moskowitz A; Berg KM; Liu X; Balaji L; Donnino MW; Grossestreuer AV
Contemp Clin Trials; 2024 Apr; 139():107486. PubMed ID: 38431131
[TBL] [Abstract][Full Text] [Related]
38. Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.
Bravaccini S; Fonzi E; Tebaldi M; Angeli D; Martinelli G; Nicolini F; Parrella P; Mazza M
Cell Transplant; 2021; 30():963689721991477. PubMed ID: 33522308
[TBL] [Abstract][Full Text] [Related]
39. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.
Strich JR; Tian X; Samour M; King CS; Shlobin O; Reger R; Cohen J; Ahmad K; Brown AW; Khangoora V; Aryal S; Migdady Y; Kyte JJ; Joo J; Hays R; Collins AC; Battle E; Valdez J; Rivero J; Kim IH; Erb-Alvarez J; Shalhoub R; Chakraborty M; Wong S; Colton B; Ramos-Benitez MJ; Warner S; Chertow DS; Olivier KN; Aue G; Davey RT; Suffredini AF; Childs RW; Nathan SD
Clin Infect Dis; 2022 Aug; 75(1):e491-e498. PubMed ID: 34467402
[TBL] [Abstract][Full Text] [Related]
40. Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection.
Guardado-Mendoza R; Garcia-Magaña MA; Martínez-Navarro LJ; Macías-Cervantes HE; Aguilar-Guerrero R; Suárez-Pérez EL; Aguilar-García A
Sci Rep; 2022 Jan; 12(1):536. PubMed ID: 35017617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
